Hills C A, Kelland L R, Abel G, Siracky J, Wilson A P, Harrap K R
Drug Development Section, Institute of Cancer Research, Belmont, Sutton, Surrey, UK.
Br J Cancer. 1989 Apr;59(4):527-34. doi: 10.1038/bjc.1989.108.
Ten human ovarian carcinoma cell lines have been studied as a potential in vitro screen for the development of novel anticancer platinum complexes. Lines have been established and developed both from solid and ascitic tumours, from pretreated and untreated patients, and are available at a range of in vitro passage numbers. The biological properties of the lines were consistent with them being human, epithelial and of ovarian carcinoma origin. Using a tritiated thymidine or leucine uptake method, and a 96 hour continuous drug exposure, the lines have been calibrated against four platinum-containing chemotherapeutic agents: cisplatin, iproplatin, carboplatin and tetraplatin. Striking differences in cytotoxicity were observed across the lines for each agent. Some lines were consistently resistant, others generally sensitive, whereas some showed clear evidence of differential sensitivity to a particular agent. Statistical analysis (Spearman rank correlation) involving the six possible pairings of drugs showed that cisplatin, iproplatin and carboplatin elicit a very similar pattern of response in these lines whereas tetraplatin elicits a completely different response pattern. Similar cytotoxicity values were obtained using a soft agar cloning assay. Results using a tetrazolium dye reduction assay, however, gave somewhat higher and more variable values, particularly with tetraplatin. The thymidine uptake assay will be adopted in further studies on a selected panel of six lines. This panel encompasses the spectra of sensitivities identified for each of the four agents against the original ten lines and may provide a useful screening facility for the development of novel platinum drugs, in that it detects both cell line-determined and structure-determined differences in cytotoxicity.
已经对十种人卵巢癌细胞系进行了研究,作为开发新型抗癌铂配合物的潜在体外筛选模型。这些细胞系既从实体瘤和腹水瘤中建立和培养而来,供体包括经预处理和未经预处理的患者,且具有一系列不同的体外传代次数。这些细胞系的生物学特性与其来源为人类、上皮细胞且源自卵巢癌相符。使用氚标记胸腺嘧啶核苷或亮氨酸摄取法,并进行96小时的连续药物暴露,已针对四种含铂化疗药物对这些细胞系进行了校准:顺铂、异丙铂、卡铂和四铂。对于每种药物,各细胞系之间观察到了显著的细胞毒性差异。一些细胞系始终具有抗性,另一些通常敏感,而有些则明显表现出对特定药物的敏感性差异。涉及六种可能药物配对的统计分析(Spearman等级相关性)表明,顺铂、异丙铂和卡铂在这些细胞系中引发非常相似的反应模式,而四铂引发完全不同的反应模式。使用软琼脂克隆试验获得了相似的细胞毒性值。然而,使用四唑盐染料还原试验得到的值略高且更具变异性,尤其是对于四铂。在对选定的六个细胞系组成的小组进行的进一步研究中将采用胸腺嘧啶核苷摄取试验。该小组涵盖了针对原始十个细胞系中每种药物所确定的敏感性谱,并且可能为新型铂类药物的开发提供有用的筛选工具,因为它能检测细胞系决定的和结构决定的细胞毒性差异。